EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sinbaglustat ameliorates disease pathology in a murine model of GM1 gangliosidosis without affecting CNS ganglioside levels

Rouven Wannemacher, Lorna Jubran-Rudolf, Isabel Zdora, Eva Leitzen, Karl Rohn, Virginie Sippel, Christoph Paschen, Peter Blattmann, Wolfgang Baumgärtner, Ingo Gerhauser, Michel Alexander Steiner

Neurobiology of Disease · 2025

DOI: 10.1016/j.nbd.2025.106917 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neurobiology of Disease, 2025. Verfasst von Rouven Wannemacher und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Veterinary Medicine Hannover, Foundation, Bünteweg 17, 30559 Hannover, Germany; Center for Systems Neuroscienc…. Hauptthemen laut MEDLINE: Gangliosidosis, GM1, Brain, Gangliosides, Thiones. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Stiftung Tierärztliche Hochschule Hannover, Idorsia Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sinbaglustat is a brain-penetrating small molecule that inhibits the non-lysosomal glucocerebrosidase (GBA2) and, with lower potency, glucosylceramide synthase (GCS). Sinbaglustat has passed clinical phase I. Our preclinical study assessed its efficacy in a transgenic mouse model of GM1 gangliosidosis, lacking a functional β-galactosidase enzyme (Glb1-/-). Starting at 4 weeks of age, mice were either treated with a nominal dose of 10 or 300 mg/kg/day of sinbaglustat or remained untreated. Wild-type (WT) mice served as control. Body weight, clinical and neurological signs, and motor function was assessed until 17-18 weeks (4 months) and 30 weeks (7 months) of age when mice were euthanized for ex vivo assessments. In comparison to WT, Glb1-/- mice showed the expected accumulation of GM1 gangliosidosis-related sphingolipids, neuropathology, and behavioral deficits. Both dosages of sinbaglustat left GM1 and lyso GM1 levels in the brain unaffected but delayed the onset of motor impairment and progression of clinical disease in Glb1-/- mice with the higher dose being more efficacious. Histologically and immunohistochemically, both treatment groups of Glb1-/- mice displayed reduced neuronal vacuolation. Only the higher dose of sinbaglustat decreased axonal damage and astrogliosis, which was also associated with a decrease of the axonal/neuronal damage marker plasma neurofilament light at 4 months (17-18 weeks). Both doses of sinbaglustat increased the GBA2 substrate glucosylceramide (GluCer) in the brain, while only the high dose reduced GluCer and other glycosphingolipids (GSLs) in the periphery indicating additional inhibition of GCS. We conclude that sinbaglustat had a therapeutic-like effect in the GM1 gangliosidosis mouse model.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gangliosidosis, GM1BrainGangliosidesThionesAnimalsDisease Models, AnimalMice, TransgenicMicebeta-GalactosidaseMice, KnockoutMice, Inbred C57BLMaleEnzyme InhibitorsMorpholines

Stichwörter der Autor:innen

Axonal damageBrainG(M1) gangliosidosisNeurofilament lightSinbaglustatSubstrate reduction therapyβ-galactosidase deficiency

Substanzen

Gangliosidesbeta-GalactosidaseThionesRV 538Enzyme InhibitorsMorpholines

Autor:innen und Institutionen

  • Department of Pathology, University of Veterinary Medicine Hannover, Foundation, Bünteweg 17, 30559 Hannover, Germany; Center for Systems Neuroscience, Hannover, Germany.
  • Department of Pathology, University of Veterinary Medicine Hannover, Foundation, Bünteweg 17, 30559 Hannover, Germany.
  • Department of Biometry, Epidemiology and Data processing, University of Veterinary Medicine Hannover, Bünteweg 12, 30559 Hannover, Germany.
  • Idorsia Pharmaceuticals Ltd., Hegenheimermattweg 91, 4123 Allschwil, Switzerland.
  • Department of Pathology, University of Veterinary Medicine Hannover, Foundation, Bünteweg 17, 30559 Hannover, Germany; Center for Systems Neuroscience, Hannover, Germany. Electronic address: wolfgang.baumgaertner@tiho-h…

Förderung

  • Stiftung Tierärztliche Hochschule Hannover
  • Idorsia Pharmaceuticals

Zitieren

APA

Wannemacher, R., Jubran-Rudolf, L., Zdora, I., Leitzen, E., Rohn, K., Sippel, V., Paschen, C., Blattmann, P., Baumgärtner, W., Gerhauser, I., & Steiner, M. A. (2025). Sinbaglustat ameliorates disease pathology in a murine model of GM1 gangliosidosis without affecting CNS ganglioside levels. Neurobiology of Disease. https://doi.org/10.1016/j.nbd.2025.106917

Vancouver

Wannemacher R, Jubran-Rudolf L, Zdora I, Leitzen E, Rohn K, Sippel V, et al. Sinbaglustat ameliorates disease pathology in a murine model of GM1 gangliosidosis without affecting CNS ganglioside levels. Neurobiology of Disease. 2025. doi:10.1016/j.nbd.2025.106917

BibTeX
@article{Wannemacher2025,
  author = {Wannemacher, Rouven and Jubran-Rudolf, Lorna and Zdora, Isabel and Leitzen, Eva and Rohn, Karl and Sippel, Virginie and Paschen, Christoph and Blattmann, Peter and Baumgärtner, Wolfgang and Gerhauser, Ingo and Steiner, Michel Alexander},
  title = {Sinbaglustat ameliorates disease pathology in a murine model of GM1 gangliosidosis without affecting CNS ganglioside levels},
  journal = {Neurobiology of Disease},
  year = {2025},
  doi = {10.1016/j.nbd.2025.106917}
}
Kostenlos starten →